Quantcast

Latest Bioethics Stories

2014-03-07 23:22:43

Art Caplan will discuss "End of Life: Legal, Medical and Ethical Issues" for the annual Batdorf Lecture at Alvernia University, March 18, 2014. Reading, PA (PRWEB) March 07, 2014 Art Caplan, considered one of the foremost experts on Bioethics and the ethics of healthcare reform, will discuss the legal, medical and ethical issues surrounding end of life for Alvernia University’s annual Batdorf Lecture, March 18, 5 p.m., in the McGlinn Conference Center. The lecture will be...

2014-03-05 08:20:33

Hawaii Biotech Receives DoD Contract to Develop Anti-Botulism Drug HONOLULU, March 5, 2014 /PRNewswire/ -- The Department of Defense, Defense Threat Reduction Agency, has awarded Hawaii Biotech, Inc., a contract to continue developing drugs to block botulinum toxin, the toxin that causes the life-threatening disease, botulism. There is no therapeutic drug currently available for the treatment of botulism. The award has a first-year period of performance through early 2014, followed...

2014-03-03 08:31:20

6.8% improvement in FEV1 versus placebo in high FENO subset representing half of treated patients BOULDER, Colo., March 3, 2014 /PRNewswire/ -- Array BioPharma Inc. (NASDAQ: ARRY) reported full results from a randomized Phase 2 trial of ARRY-502 in patients with mild to moderate Th2-Driven Asthma at the 2014 American Academy Of Allergy, Asthma & Immunology (AAAAI) Annual Meeting. http://photos.prnewswire.com/prnvar/20121029/LA02195LOGO ARRY-502, an oral CRTh2 antagonist, was studied in a...

2014-02-25 08:31:00

- Study Meets Primary and Both Key Secondary Endpoints - BRISBANE, Calif., Feb. 25, 2014 /PRNewswire/ -- InterMune, Inc. (NASDAQ: ITMN) today announced that top-line data from ASCEND, a Phase 3 trial evaluating pirfenidone in patients with idiopathic pulmonary fibrosis (IPF), demonstrated that pirfenidone significantly reduced IPF disease progression as measured by change in percent predicted forced vital capacity (FVC) from Baseline to Week 52 (rank ANCOVA p<0.000001)....

2014-02-18 08:29:35

MELBOURNE, Australia and NEW YORK, Feb. 18, 2014 /PRNewswire/ -- Key Points: -- Primary endpoints of safety and tolerability met. -- Secondary endpoint: Statistically significant improvement in a measure of executive function(cognition) in research participants administered 250mg PBT2 daily (p=0.042). -- PBT2 250mg was also associated with a favourable signal in functional capacity. -- Preliminary evidence suggests PBT2 250mg reduced atrophy of...

2014-02-14 23:01:28

Results from Alpha BRAIN™ Pilot Study to Be Presented at the International Neuropsychological Society Annual Conference Austin, Texas (PRWEB) February 14, 2014 Results from a pilot study entitled “A Proof of Concept Study for a Randomized Double-Blind, Placebo Controlled, Parallel Group, Efficacy Study of Alpha BRAIN™ Administered Orally,” conducted by the Boston Center for Memory will be presented at the annual International Neuropsychological Society (INS) meeting in Seattle,...

2014-02-13 23:26:17

All proceeds from this special photo shoot will benefit homeless dogs and cats. Washington, DC (PRWEB) February 13, 2014 Lucky Dog Animal Rescue and Houndstooth Photography will be holding a Valentine’s Photo shoot on Saturday, February 15th at Wagtime, 1232 9th Street, NW, Washington, DC. The shoot will be from 11 am to 1 pm. The $35 dollar sitting fee will be donated to Lucky Dog Animal Rescue. Prints can be ordered from Houndstooth Photography for an additional charge. Pet...

2014-02-11 23:30:44

The nonprofit organization, Animals for Armed Forces® Foundation, appreciates the support of Julian Omidi and Dr. Michael Omidi and their charity Animal Support. They look forward to expanding their calendar of free pet adoption events for members of the United States military. (PRWEB) February 11, 2014 Animal Support and its charity cofounders, Dr. Michael Omidi and Julian Omidi, recently received the thanks for supporting the work of Animals for Armed Forces Foundation®, a...

2014-02-11 08:32:36

Company continues to expand its board and leadership team as it moves toward completion of its Phase 3 gene therapy program and advancement of the industry's deepest pipeline of gene-based medicines PHILADELPHIA, Feb. 11, 2014 /PRNewswire/ -- Spark Therapeutics, a late-stage company developing gene-based medicines for a wide range of debilitating diseases, announced today the appointment of Elliott Sigal, M.D., Ph.D., former director, executive vice president and chief scientific officer of...

2014-02-11 08:27:28

SEATTLE, Feb. 11, 2014 /PRNewswire-USNewswire/ -- Are humans the enemy? Should pigs and peas have constitutional rights? The War on Humans, a provocative 31-minute documentary from Discovery Institute exploring growing efforts to disparage the value of humans in the name of saving the planet, will be released online February 18(th) at www.waronhumans.com. The documentary features bioethicist and Discovery Institute Senior Fellow Wesley J. Smith, who has authored a companion e-book...


Latest Bioethics Reference Libraries

OncoMouse
2013-10-02 09:29:43

The OncoMouse or Harvard Mouse is a type of laboratory mouse that has been genetically modified utilizing modification designed by Philip Leder and Timothy A. Stewart, of Harvard University, to carry a certain gene called an activated oncogene. The activated oncogene considerably increases the mouse’s vulnerability to cancer, therefore making the mouse suitable for cancer research. The rights to the invention were owned by DuPont until recently. The USPTO found that the patent expired in...

More Articles (1 articles) »
Word of the Day
glogg
  • Scandinavian punch made of claret and aquavit with spices and raisins and orange peel and sugar.
This word comes from the Swedish 'glogg,' which is an alteration of 'glodgat,' mulled (wine).
Related